{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:39:36Z","timestamp":1790995176648,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"am","delay-in-days":256,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.neuropharm.2023.109601","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T11:23:17Z","timestamp":1685964197000},"page":"109601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Conditional deletion of CB2 cannabinoid receptors from peripheral sensory neurons eliminates CB2-mediated antinociceptive efficacy in a mouse model of carrageenan-induced inflammatory pain"],"prefix":"10.1016","volume":"237","author":[{"given":"Kelsey G.","family":"Guenther","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhili","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2897-606X","authenticated-orcid":false,"given":"Julian","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia J.","family":"Hillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8501-6199","authenticated-orcid":false,"given":"Ken","family":"Mackie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0941-6435","authenticated-orcid":false,"given":"Andrea G.","family":"Hohmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2023.109601_bib1","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.pain.2008.06.007","article-title":"Cannabinoid receptor CB2 localisation and agonist-mediated inhibition of capsaicin responses in human sensory neurons","volume":"138","author":"Anand","year":"2008","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2023.109601_bib2","series-title":"32nd Annual Symposium of the International Cannabinoid Research Society","article-title":"Cell specific roles of the CB2R in the acute locomotor response to cocaine [abstract]","author":"Behlke","year":"2022"},{"key":"10.1016\/j.neuropharm.2023.109601_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1191\/0269216304pm845ra","article-title":"Gabapentin in the treatment of neuropathic pain","volume":"18","author":"Bennett","year":"2004","journal-title":"Palliat. Med."},{"key":"10.1016\/j.neuropharm.2023.109601_bib5","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1080\/14728222.2021.1971196","article-title":"The CB2 cannabinoid receptor as a therapeutic target in the central nervous system","volume":"25","author":"Caba\u00f1ero","year":"2021","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.neuropharm.2023.109601_bib6","article-title":"Peripheral sensory neuron CB2 cannabinoid receptors are necessary for both CB2-mediated antinociceptive efficacy and sparing of morphine tolerance in a mouse model of anti-reroviral toxic neuropathy","volume":"187","author":"Carey","year":"2023","journal-title":"Pharma Res."},{"key":"10.1016\/j.neuropharm.2023.109601_bib7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0304-3959(01)00454-7","article-title":"CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain","volume":"96","author":"Clayton","year":"2002","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2023.109601_bib8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1080\/09540260902782752","article-title":"Actions of delta-9-tetrahydrocannabinol in cannabis: relation to use, abuse, dependence","volume":"21","author":"Cooper","year":"2009","journal-title":"Int. Rev. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109601_bib9","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.biopsych.2014.04.009","article-title":"Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal","volume":"77","author":"Deng","year":"2015","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109601_bib11","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.pain.2005.09.005","article-title":"Activation of CB1 and CB2 receptors attenuates the induction and maintenance of inflammatory pain in the rat","volume":"118","author":"Elmes","year":"2005","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2023.109601_bib12","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1432-1033.1995.tb20780.x","article-title":"Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations","volume":"232","author":"Gali\u00e8gue","year":"1995","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.neuropharm.2023.109601_bib13","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/ptr.2686","article-title":"Effects of hydroxytyrosol-20 on carrageenan-induced acute inflammation and hyperalgesia in rats","volume":"23","author":"Gong","year":"2008","journal-title":"Phytother Res."},{"key":"10.1016\/j.neuropharm.2023.109601_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.101999","article-title":"Cannabinoid CB2 receptors are upregulated via bivalent histone modifications and control primary afferent input to the spinal cord in neuropathic pain","volume":"298","author":"Ghosh","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2023.109601_bib15","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/sj.bjp.0707531","article-title":"Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain","volume":"153","author":"Guidon","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109601_bib16","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1016\/j.pain.2011.03.038","article-title":"Self-medication of a cannabinoid CB2 agonist in an animal model of neuropathic pain","volume":"152","author":"Gutierrez","year":"2011","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2023.109601_bib17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/sj.bjp.0706984","article-title":"Activation of peripheral cannabinoid CB1 and CB2 receptors supresses the maintenance of inflammatory nociception: a comparative analysis","volume":"150","author":"Gutierrez","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109601_bib18","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1124\/jpet.103.060079","article-title":"Selective activation of cannabinoid CB2 receptors supresses hyperalgesia evoked by intradermal capsaicin","volume":"308","author":"Hohmann","year":"2004","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2023.109601_bib19","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0306-4522(99)00220-1","article-title":"Cannabinoid receptors undergo axonal flow in sensory nerves","volume":"92","author":"Hohmann","year":"1999","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2023.109601_bib20","doi-asserted-by":"crossref","first-page":"5722","DOI":"10.1021\/jm400305d","article-title":"Selective cannabinoid receptor type 2 (CB2) agonists: optimization of a series of purines leading to the identification of a clinical candidate for the treatment of osteoarthritic pain","volume":"56","author":"Hollinshead","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2023.109601_bib21","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1124\/pr.54.2.161","article-title":"International union of Pharmacology. XXVII. Classification of cannabinoid receptors","volume":"54","author":"Howlett","year":"2002","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2023.109601_bib22","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1476-5381.2010.01046.x","article-title":"Central and peripheral sites of action for CB\u2082 receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats","volume":"162","author":"Hsieh","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109601_bib23","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0077-18.2018","article-title":"Advillin is expressed in all adult neural crest-derived neurons","volume":"5","author":"Hunter","year":"2018","journal-title":"eNeuro"},{"key":"10.1016\/j.neuropharm.2023.109601_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173544","article-title":"The cannabinoid CB2 receptor agonist LY2828360 synergizes with morphine to suppress neuropathic nociception and attenuates morphine reward and physical dependence","volume":"886","author":"Iyer","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109601_bib25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/mol.117.109355","article-title":"Slowly signaling G-protein biased CB2 cannabinoid receptor agonist LY2828360 supresses neuropathic pain with sustained efficacy and attenuates morphine tolerance and dependence","volume":"93","author":"Lin","year":"2018","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109601_bib26","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1097\/j.pain.0000000000002502","article-title":"A peripheral CB2 cannabinoid receptor mechanism suppresses chemotherapy-induced peripheral neuropathy: evidence from a CB2 reporter mouse","volume":"163","author":"Lin","year":"2022","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2023.109601_bib27","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.neuropharm.2023.109601_bib28","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12974-018-1174-9","article-title":"Cannabinoid CB2 receptors in the mouse brain: relevance for Alzheimer's disease","volume":"15","author":"L\u00f3pez","year":"2018","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2023.109601_bib29","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ejp.1148","article-title":"Current evidence of cannabinoid-based analgesia obtained in preclinical and human experimental settings","volume":"22","author":"L\u00f6tsch","year":"2018","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.neuropharm.2023.109601_bib30","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0304-3959(01)00321-9","article-title":"CB2 cannabinoid receptor-mediated peripheral anti-nociception","volume":"93","author":"Malan","year":"2001","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2023.109601_bib31","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0009-3084(02)00155-X","article-title":"Inhibition of pain responses by activation of CB2 cannabinoid receptors","volume":"121","author":"Malan","year":"2002","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.neuropharm.2023.109601_bib32","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/365061a0","article-title":"Molecular characterization of a peripheral receptor for cannabinoids","volume":"365","author":"Munro","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2023.109601_bib33","doi-asserted-by":"crossref","first-page":"42","DOI":"10.2174\/15748898112079990016","article-title":"Different classes of CB2 ligands potentially useful in the treatment of pain","volume":"8","author":"Murineddu","year":"2013","journal-title":"Recent Pat. CNS Drug Discov."},{"key":"10.1016\/j.neuropharm.2023.109601_bib34","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0306-4522(03)00126-X","article-title":"Selective activation of cannabinoid CB2 receptors suppresses spinal Fos protein expression and pain behavior in a rat model of inflammation","volume":"119","author":"Nackley","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2023.109601_bib35","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0306-4522(02)00870-9","article-title":"A peripheral cannabinoid mechanism supresses spinal Fos protein expression and pain behavior in a rat model of inflammation","volume":"117","author":"Nackley","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2023.109601_bib36","doi-asserted-by":"crossref","first-page":"3562","DOI":"10.1152\/jn.00886.2003","article-title":"Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation","volume":"92","author":"Nackley","year":"2004","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2023.109601_bib37","first-page":"S56","article-title":"A proof-of concept (poc) study including experimental pain models (epms) to assess the effecrs of a CB2 agonist (LY2828360) in the treatment of patients with osteoarthritic (oa) knee pain","volume":"93","author":"Pereira","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2023.109601_bib38","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0306-4522(03)00333-6","article-title":"The neuronal distribution of cannabinoid receptor type 1 in the trigeminal ganglion of the rat","volume":"120","author":"Price","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2023.109601_bib39","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/00000542-200310000-00031","article-title":"Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors","volume":"99","author":"Quartilho","year":"2003","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neuropharm.2023.109601_bib40","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/s11481-015-9611-3","article-title":"A CB2-selective cannabinoid supresses T-cell activities and increases Tregs and IL-10","volume":"10","author":"Robinson","year":"2015","journal-title":"J. Neuroimmune Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109601_bib42","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1021\/acsptsci.9b00049","article-title":"Cannabinoid receptor 2 (CB2) signals via G-alpha-s and induces IL-6 and IL-10 cytokine secretion in human primary leukocytes","volume":"2","author":"Saroz","year":"2019","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.neuropharm.2023.109601_bib43","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1097\/j.pain.0000000000002269","article-title":"Systematic review and meta-analysis of cannabinoids, cannabis-based medicines, and endocannabinoid system modulators tested for antinociceptive effects in animal models of injury-related or pathological persistent pain","volume":"162","author":"Soliman","year":"2021","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2023.109601_bib44","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj8186","article-title":"Spatial transcriptomics of dorsal root ganglia identifies molecular signatures of human nociceptors","volume":"14","author":"Tavares-Ferreira","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neuropharm.2023.109601_bib46","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1126\/science.1115740","article-title":"Identification and functional characterization of brainstem cannabinoid CB2 receptors","volume":"310","author":"Van Sickle","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2023.109601_bib48","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.neuroscience.2005.06.009","article-title":"Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons","volume":"135","author":"Wotherspoon","year":"2005","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2023.109601_bib49","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/nn.2874","article-title":"Brain cannabinoid CB(2) receptors modulate cocaine's actions in mice","volume":"14","author":"Xi","year":"2011","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109601_bib50","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.immuni.2012.12.001","article-title":"Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis","volume":"38","author":"Yona","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.neuropharm.2023.109601_bib51","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0069-16.2017","article-title":"Sensory neuron-specific deletion of TRPA1 results in mechanical cutaneous sensory deficits","volume":"4","author":"Zappia","year":"2017","journal-title":"eNeuro"},{"key":"10.1016\/j.neuropharm.2023.109601_bib52","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8508906","article-title":"Diallyl disulfide supresses inflammatory and oxidative machineries following carrageenan injection-induced paw edema in mice","volume":"2020","author":"Zhang","year":"2020","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.neuropharm.2023.109601_bib53","doi-asserted-by":"crossref","first-page":"9424","DOI":"10.1073\/pnas.0914725107","article-title":"Deletion of PIK3C3\/Vps34 in sensory neurons causes rapid neurodegeneration by disrupting the endosomal but not the autophagic pathway","volume":"17","author":"Zhou","year":"2010","journal-title":"Proc Netl Acad Sci. USA"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390823001910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390823001910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:25:19Z","timestamp":1758439519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390823001910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":48,"alternative-id":["S0028390823001910"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109601","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Conditional deletion of CB2 cannabinoid receptors from peripheral sensory neurons eliminates CB2-mediated antinociceptive efficacy in a mouse model of carrageenan-induced inflammatory pain","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109601","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109601"}}